# Unraveling metabolic dependencies in H3K27M mutant Diffuse Intrinsic Pontine Gliomas

> **NIH NIH R01** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2020 · $301,140

## Abstract

Project Summary/ Abstract
Despite significant advances in our understanding of the molecular drivers of Diffuse Intrinsic Pontine Gliomas
(DIPGs), there are no viable treatment options resulting in certain fatality of DIPG patients. The lack of
understanding of DIPG pathogenesis is a significant barrier to curing these aggressive tumors. More than 80%
of DIPGs bear a histone H3 mutation at lysine 27 to methionine (H3K27M) which leads to global reduction of
the repressive mark H3K27me3. Evidence implicates H3K27M as a central driver of tumorigenesis, yet the
precise mechanisms remain obscure. Elucidation of the molecular mechanisms by which H3K27M mutations
drive cancer and the precise mechanisms that regulate H3K27me3 could illuminate potential therapeutic
approaches. One of the fundamental mechanisms driving cancer cell survival and growth is reprograming of
cellular metabolism by oncogenes, which enables increased uptake and metabolism of nutrients such as
glucose and glutamine by tumors. Glutamine is the most abundant plasma amino acid, which supports
uncontrolled growth and proliferation of cancer cells. Glutamine is metabolized to α-ketoglutarate (αKG), which
serves as a substrate for the tricarboxylic acid (TCA) cycle and is thereby critical for ATP synthesis, redox
homeostasis and production of biomolecules. More importantly, glutamine-derived αKG is a critical cofactor for
the H3K27 histone lysine demethylases (KDMs) that can drive global reduction of H3K27me3. Glutamine is
therefore at the crossroads of several intersecting pathways, both a critical metabolite that supports cancer
growth and a cofactor to drive H3K27me3 reduction that is central to pathogenesis of H3K27M mutant DIPGs.
Our global hypothesis is that H3K27M DIPG cells rewire both cellular metabolism and epigenetics via
glutamine to sustain uncontrolled tumor growth and proliferation. Three specific aims will address this
hypothesis: Aim 1. Define glutamine metabolism and elucidate the epigenetic mechanisms by which H3K27M
enhances glutamine metabolism. Aim 2. Interrogate the molecular mechanisms by which glutamine
metabolism regulates global H3K27me3 reduction. Aim 3. Elucidate the therapeutic potential of targeting
glutamine metabolism as proof-of-principle. The combination of these three aims will address significant gaps
in our understanding of DIPGs and lay the groundwork to develop effective treatments.

## Key facts

- **NIH application ID:** 9998033
- **Project number:** 5R01NS110572-02
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Sriram Venneti
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $301,140
- **Award type:** 5
- **Project period:** 2019-09-01 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9998033

## Citation

> US National Institutes of Health, RePORTER application 9998033, Unraveling metabolic dependencies in H3K27M mutant Diffuse Intrinsic Pontine Gliomas (5R01NS110572-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9998033. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*